Article
Rheumatology
Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, Paul Martin, Tina Thomson, Paul Randell, Anand Shah, Aran Singanayagam, Liz Lightstone, Alison Cox, Peter Kelleher, Michelle Willicombe, Stephen P. McAdoo
Summary: SARS-CoV-2 vaccines are immunogenic in patients receiving immunosuppression, though the response is impaired compared to healthy individuals. B-cell depletion following rituximab impairs serological responses, but T-cell responses are preserved in this group. Repeat vaccine doses for serological non-responders could be considered to induce more robust immunological response.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
M. Bondareva, P. Letz, K. Karberg, E. Schrezenmeier, I Semin, H. Rincon-Arevalo, T. Doerner, M. F. Mashreghi, A-L Stefanski, A. A. Kruglov
Summary: Systemic vaccination against SARS-CoV-2 induces high levels of specific antibodies in the blood and oral cavity. However, patients with rheumatoid arthritis (RA) and undergoing B cell depletion treatment have a higher risk of severe COVID-19 manifestation and breakthrough infections. This study found that the levels of secreted antibodies in the oral cavity were correlated with B cell numbers in the blood. Importantly, a third dose vaccination efficiently induced anti-Spike antibody responses in the saliva of RA patients, similar to healthy individuals.
JOURNAL OF AUTOIMMUNITY
(2022)
Article
Medicine, General & Internal
Eun Song Kang, Ji Seon Oh, Eun-Ju Lee, Seokchan Hong, Soo Min Ahn, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim
Summary: This study investigated the effects of the third dose of the mRNA vaccine on antibody titer and factors associated with antibody production in rheumatoid arthritis (RA) patients who had received two doses of the ChAdOx1-S nCoV-19 vaccine. The study found that the group with the third mRNA vaccine had a higher positive rate of high antibody titers. Multivariate analysis showed that corticosteroid use, older age, and male sex were associated with a lower rate of high antibody titer acquisition after two doses of ChAdOx1-S nCoV-19. Overall, the third dose of the mRNA vaccine could be beneficial for RA patients.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Review
Immunology
Antonio Bertoletti, Nina Le Bert, Martin Qui, Anthony T. Tan
Summary: Virus-specific T cells during SARS-CoV-2 infection can play a dual role in either protection or pathogenesis, highlighting the importance of studying the function of these cells for future therapeutic and preventative strategies.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Immunology
Giovanni Striani, Ariela Hoxha, Mariagrazia Lorenzin, Giacomo Cozzi, Laura Scagnellato, Tatiana Vangelista, Francesca Frizzera, Pierino De Sandre, Paolo Simioni, Andrea Doria, Roberta Ramonda
Summary: This study investigated the effects of SARS-CoV-2 infection and vaccination in patients with inflammatory arthritis (IA). It found that IA patients who contracted SARS-CoV-2 infection had a higher rate of arthritis flare, and IA patients may also experience flare-ups after SARS-CoV-2 vaccination, although not statistically significant.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Kexin Liu, Jinyu Li, Gaosi Xu
Summary: This study analyzed the optimal interval before SARS-CoV-2 vaccination for patients who had previously received anti-CD20 monoclonal antibodies. The results suggested that the optimal interval after the final dose of anti-CD20 monoclonal antibody was 5.5 months.
Article
Immunology
Simona Arientova, Katerina Matuskova, Oldrich Bartos, Michal Holub, Ondrej Beran
Summary: This study examined the dynamics and duration of immune responses after a three-dose regimen of the BNT162b2 mRNA vaccine. The results showed that the vaccine induced potent and enduring humoral and cellular immune responses, with enhanced protection after the third dose that remained stable up to a year later.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Andreas Tornell, Hanna Grauers Wiktorin, Johan Ringlander, Mohammad Arabpour, Staffan Nilsson, Magnus Lindh, Martin Lagging, Kristoffer Hellstrand, Anna Martner
Summary: This study analyzed the magnitude and duration of SARS-CoV-2-specific T cell responses in healthy individuals receiving COVID-19 vaccines. The results showed that vaccination triggered a strong T cell response, with levels of the cytokine interleukin-2 exceeding pre-vaccination levels. The S1-specific T cell reactivity was stronger in vaccinated individuals compared to those recovering from natural COVID-19 and decayed over time. The study concludes that COVID-19 vaccination induces robust T cell immunity that subsequently declines.
CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Ana-Luisa Stefanski, Hector Rincon-Arevalo, Eva Schrezenmeier, Kirsten Karberg, Franziska Szelinski, Jacob Ritter, Yidan Chen, Bernd Jahrsdoerfer, Carolin Ludwig, Hubert Schrezenmeier, Andreia C. Lino, Thomas Doerner
Summary: By analyzing the B cell and T cell data before receiving rituximab (RTX) treatment, it is possible to predict the response to vaccination in patients with autoimmune inflammatory rheumatic diseases. The study found that B cells of vaccination responders in the RTX group were mainly naive and transitional cells, while vaccination non-responders had a higher proportion of plasmablasts and double negative B cells. There was also a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5, and an inverse correlation with CD95 and CD21low expression. Adequate repopulation of the naive B cell compartment after RTX therapy and expression of exhaustion markers both affect vaccination response.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Henning Jacobsen, Viviana Cobos Jimenez, Ioannis Sitaras, Naor Bar-Zeev, Luka Cicin-Sain, Melissa M. M. Higdon, Maria Deloria-Knoll
Summary: This mini review summarizes the evidence on T cell immunity against the omicron variant and indicates that vaccines utilizing the parental antigen continue to provide protection against disease caused by omicron.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Maurizio Benucci, Arianna Damiani, Francesca Li Gobbi, Barbara Lari, Valentina Grossi, Maria Infantino, Mariangela Manfredi
Summary: This study on 200 patients with rheumatoid arthritis receiving BNT162b2 vaccination found that the background therapy can influence seroconversion, especially for patients treated with ABA and RTX. Despite the booster vaccine, patients under certain treatments had lower levels of anti-SARS CoV-2 IgG.
IMMUNOLOGIC RESEARCH
(2022)
Article
Immunology
Ayse Unal Enginar
Summary: While most COVID-19 patients have mild symptoms, a small percentage may develop severe pneumonia or even arthritis. Some patients may experience joint pain or arthritis after receiving the COVID-19 vaccine.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Domenico Lo Tartaro, Annamaria Paolini, Marco Mattioli, Julian Swatler, Anita Neroni, Rebecca Borella, Elena Santacroce, Alessia Di Nella, Licia Gozzi, Stefano Busani, Michela Cuccorese, Tommaso Trenti, Marianna Meschiari, Giovanni Guaraldi, Massimo Girardis, Cristina Mussini, Katarzyna Piwocka, Lara Gibellini, Andrea Cossarizza, Sara De Biasi
Summary: By using polychromatic flow cytometry and complex data analyses, the authors investigated the immune memory response in recovered COVID-19 individuals and vaccinated individuals. They found that there were differences in the phenotypic and functional properties of adaptive immunity between the two groups, particularly in terms of T cell polarization, B cell activation, and cytokine production.
FRONTIERS IN IMMUNOLOGY
(2023)
Editorial Material
Immunology
Andrea Jarisch, Eliza Wiercinska, Shabnam Daqiq-Mirdad, Helen Hellstern, Salem Ajib, Anjali Cremer, Ngoc Thien Thu Nguyen, Alexandra Dukat, Evelyn Ullrich, Sandra Ciesek, Kai-Uwe Chow, Hubert Serve, Erhard Seifried, Peter Bader, Halvard Bonig, Gesine Bug
Summary: Little is known about the cellular immune response to SARS-CoV-2 vaccination in patients after hematopoietic stem cell transplant (HSCT) and with iatrogenic B-cell aplasia. In nonseroconverted HSCT patients, specific T-cell responses were assessed. Most allogeneic HSCT patients who did not show humoral responses to vaccination also failed to mount antigen-specific T-cell responses.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2022)
Article
Immunology
Michalis Liontos, Evangelos Terpos, Christos Markellos, Flora Zagouri, Alexandros Briasoulis, Ioanna Katsiana, Efthymia Skafida, Oraianthi Fiste, Elena Kunadis, Angeliki Andrikopoulou, Maria Kaparelou, Konstantinos Koutsoukos, Maria Gavriatopoulou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos
Summary: Vaccination for SARS-CoV-2 offers significant protection in the general population, but cancer patients under treatment show lower levels of neutralizing antibodies and require further investigation for their immunity status.
